ROCKVILLE, Md., 2013-09-18 00:24 CEST(GLOBE NEWSWIRE) -- Novavax, Inc.(Nasdaq:NVAX), a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines and vaccine adjuvants, today announced that it will host the Analyst and Investor Update Call with Webcast on Tuesday, September 24, 2013, from 9:00 a.m. - 11:00 a.m. (EDT). Senior management, including Stanley Erck, President and Chief Executive Officer; Gregory Glenn, MD, SVP and Chief Medical Officer; Lou Fries, MD, VP of Clinical & Medical Affairs; and Gale Smith, PhD, VP of Vaccine Development, along with special guest speaker Dr. Pedro A. Piedra, Professor of Molecular Virology and Microbiology at the Baylor College of Medicine, and a key-opinion leader in the field of pediatric infectious diseases and viral respiratory illnesses, will present on the following topics: -- Corporate Overview -- Recombinant Nanoparticle Technology: an Engine for Growth -- The Novavax Influenza Programs -- The RSV Landscape -- The Novavax RSV Programs " Novavaxis excited about the opportunity to update the investor community on the development plans for our lead candidates," said Stan Erck, President and CEO. "This meeting allows us to set the stage for 2014 development and to provide some visibility into 2015." The dial-in number for the conference call is 1 (877) 212-6076 (U.S. or Canada) or 1 (707) 287-9331 (international). The webcast can be accessed via a link on the home page of the Novavaxwebsite (novavax.com) or through the "Investor Info"/"Events" tab on the Novavaxwebsite. A replay of the call will be available starting at 1:00 pmon Tuesday, September 24, 2013until midnight November 5, 2013. To access the replay by telephone, dial 1 (855) 859-2056 (U.S. or Canada) or 1 (404) 537-3406 (international) and use passcode 65051892. The replay will also be available as a webcast and can be found on the "Investor Info"/ "Events" on the Novavaxwebsite. About Novavax Novavax, Inc.(Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Novavaxis involved in several international partnerships, including collaborations with Cadila Pharmaceuticalsof India, LG Life Sciences of Koreaand PATH, and recently acquired Isconova AB, a leading vaccine adjuvant company located in Sweden. Together, Novavax' network supports its global commercialization strategy to create real and lasting change in the biopharmaceutical and vaccinology fields. Additional information about Novavaxis available on the company's website, novavax.com. Barclay PhillipsSVP, Chief Financial Officer and Treasurer Novavax, Inc.240-268-2000 Copyright © 2013 OMX AB (publ).